Versartis Inc (NASDAQ:VSAR) SVP Paul Westberg sold 1,316 shares of the business’s stock in a transaction on Wednesday, April 19th. The shares were sold at an average price of $19.85, for a total transaction of $26,122.60. Following the sale, the senior vice president now directly owns 68,228 shares of the company’s stock, valued at $1,354,325.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Paul Westberg also recently made the following trade(s):
- On Monday, February 27th, Paul Westberg sold 12,500 shares of Versartis stock. The shares were sold at an average price of $22.50, for a total transaction of $281,250.00.
- On Thursday, February 23rd, Paul Westberg sold 25,000 shares of Versartis stock. The shares were sold at an average price of $18.75, for a total transaction of $468,750.00.
- On Monday, January 30th, Paul Westberg sold 1,916 shares of Versartis stock. The shares were sold at an average price of $13.85, for a total transaction of $26,536.60.
Shares of Versartis Inc (NASDAQ:VSAR) traded down 1.99% during mid-day trading on Thursday, reaching $19.70. 163,421 shares of the company were exchanged. Versartis Inc has a 12 month low of $7.05 and a 12 month high of $24.00. The firm’s 50-day moving average is $20.47 and its 200-day moving average is $15.56. The company’s market capitalization is $690.41 million.
Versartis (NASDAQ:VSAR) last posted its earnings results on Tuesday, February 21st. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by $0.02. During the same quarter last year, the business posted ($0.69) EPS. On average, equities analysts forecast that Versartis Inc will post ($2.51) earnings per share for the current fiscal year.
Several analysts have recently issued reports on VSAR shares. Zacks Investment Research cut shares of Versartis from a “buy” rating to a “hold” rating in a research note on Thursday, January 12th. Piper Jaffray Companies boosted their price objective on shares of Versartis from $22.00 to $26.00 and gave the company an “overweight” rating in a research note on Tuesday, April 4th. Barclays PLC started coverage on shares of Versartis in a research note on Thursday, March 9th. They set an “overweight” rating and a $28.00 price objective for the company. Finally, Canaccord Genuity reissued a “buy” rating and set a $28.00 price objective on shares of Versartis in a research note on Wednesday, February 22nd. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $23.86.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN raised its position in Versartis by 107.4% in the third quarter. Wells Fargo & Company MN now owns 11,492 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 5,952 shares during the last quarter. Monashee Investment Management LLC bought a new stake in Versartis during the third quarter valued at about $1,838,000. NF Trinity Capital Hong Kong Ltd bought a new stake in Versartis during the third quarter valued at about $3,000,000. Spark Investment Management LLC bought a new stake in Versartis during the third quarter valued at about $199,000. Finally, Aisling Capital LLC raised its stake in Versartis by 10.7% in the third quarter. Aisling Capital LLC now owns 2,524,465 shares of the biopharmaceutical company’s stock valued at $30,925,000 after buying an additional 244,897 shares in the last quarter. Institutional investors and hedge funds own 70.15% of the company’s stock.
Versartis Company Profile
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/versartis-inc-vsar-svp-sells-26122-60-in-stock/1751431.html
Receive News & Ratings for Versartis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc and related companies with MarketBeat.com's FREE daily email newsletter.